Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
88.6M
-
Number of holders
-
161
-
Total 13F shares, excl. options
-
65.9M
-
Shares change
-
-108K
-
Total reported value, excl. options
-
$1.62B
-
Value change
-
-$1.53M
-
Put/Call ratio
-
0.29
-
Number of buys
-
78
-
Number of sells
-
-74
-
Price
-
$24.64
Significant Holders of Travere Therapeutics, Inc. - Common Stock (TVTX) as of Q3 2022
195 filings reported holding TVTX - Travere Therapeutics, Inc. - Common Stock as of Q3 2022.
Travere Therapeutics, Inc. - Common Stock (TVTX) has 161 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 65.9M shares
of 88.6M outstanding shares and own 74.34% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (5.84M shares), RA CAPITAL MANAGEMENT, L.P. (4.92M shares), BlackRock Inc. (4.56M shares), Deep Track Capital, LP (4M shares), JANUS HENDERSON GROUP PLC (3.91M shares), STATE STREET CORP (3.41M shares), VANGUARD GROUP INC (3.38M shares), BAKER BROS. ADVISORS LP (3.3M shares), GOLDMAN SACHS GROUP INC (2.55M shares), and ADAGE CAPITAL PARTNERS GP, L.L.C. (2.35M shares).
This table shows the top 161 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.